Alemtuzumab: a novel monoclonal antibody

Bibliography

• XIA MQ, HALE G, LIFELY MR et al.: Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. (1993) 293:633–640.
   Google Scholar
• HALE G, BRIGHT S, CHUMBLEY G et al.: Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 62:873–882.
   PubMed Web of Science ®Google Scholar
• HALE G, SWIRSKY DM, HAYHOE FG, WALDMANN H: Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Ma. Biol. Med. (1983) 1:321–334.
   Google Scholar
• WALDMANN H, POLLIAK A, HALE Get al.: Elimination of graft- versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet (1984) 2:483–486.
   Google Scholar
• HALE G, COBBOLD SP, WALDMANN H, EASTER G, MATEJTSCHUK E COOMBS RR: Isolation of low-frequency class-switch variants from rat hybrid myelomas. I ImmurroL Methods (1987) 103:59–67.
   PubMed Web of Science ®Google Scholar
• DYER MJ, HALE G, HAYHOE FG, WALDMANN H: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood (1989) 73:1431–1439.
   PubMed Web of Science ®Google Scholar
• RIECHMANN L, CLARK M, WALDMANN H, WINTER G: Reshaping human antibodies for therapy. Nature (1988) 332:323.
   PubMed Web of Science ®Google Scholar
• HALE G, DYER MJ, CLARK MR etal.: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2:1394–1399.
   Google Scholar
• HALE G, WALDMANN H: The story of Campath-1. Methods Malec. Med. (2000) 40:243-266. A thorough review of CAMPATH-1 mAb.
   Google Scholar
• FINKELSTEIN JB: FDA panel recommends two new cancer drugs for approval. I Natl. Cancer Inst. (2001) 93:175–176.
   PubMed Web of Science ®Google Scholar
• HALE G: Biology of the CD52 antigen. Chronic Lymphocytic Leukemia (2001) 6:1.
   Google Scholar
• HALE G, XIA MQ, TIGHE HE DYER MJ, WALDMANN H: The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 35:118–127.
   PubMed Web of Science ®Google Scholar
• GINALDI L, DE MARTINIS M, MATUTES E et al.: Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. (1998) 22:185–191.
   PubMed Web of Science ®Google Scholar
• •Report of the clinical relevance of CD52 level of expression.
   Google Scholar
• XIA MQ, HALE G, WALDMANN H: Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. MoL ImmurroL (1993) 30:1089–1096.
   PubMed Web of Science ®Google Scholar
• HALE G, RYE PD, WARFORD A, LAUDER I, BRITO-BABAPULLE A: The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. j Reprod. ImmurroL (1993) 23:189–205.
   PubMed Web of Science ®Google Scholar
• ROWAN W, TITE J, TOPLEY E BRETT SJ: Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology (1998) 95:427–436.
   PubMed Web of Science ®Google Scholar
• HALE G, WALDMANN H: Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood (1998) 91:3079–3083.
   PubMed Web of Science ®Google Scholar
• THEOBALD M, HOFFMANN T, BUNJES D, HEIT W: Comparative analysis of in vivo T cell depletion with radiotherapy, combination chemotherapy, and the monoclonal antibody Campath-1G, using limiting dilution methodology. Transplantation (1990) 49:553–559.
   PubMed Web of Science ®Google Scholar
• HALE G, ZHANG MJ, BUNJES D etal.: Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft- versus-host disease and graft rejection. Blood (1998) 92:4581–4590.
   Google Scholar
• OAKHILL A, PAMPHILON DH, POTTER MN et al.: Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br j HaematoL (1996) 94:574–578.
   PubMed Web of Science ®Google Scholar
• KERNAN NA, FLOMENBERG N, DUPONT B, O'REILLY RJ: Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation (1987) 43:842–847.
   Google Scholar
• CHAMPLIN RE, PASSWEG JR, ZHANG MJ et al.: T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood (2000) 95:3996–4003.
   PubMed Web of Science ®Google Scholar
• APPERLEY JF, MAURO FR, GOLDMAN JM et al.: Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft- versus-leukaemia effect. Br j HaematoL (1988) 69:239–245.
   PubMed Web of Science ®Google Scholar
• NAPARSTEK E, OR R, NAGLER A et al.: T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br. Haematol. (1995) 89:506–515.
   PubMed Web of Science ®Google Scholar
• HALE G, JACOBS P, WOOD L et al.: CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow TranspL (2000) 26:69–76.
   PubMed Web of Science ®Google Scholar
• MORGAN G, LINCH DC, KNOTT LT et al.: Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T cell removal using CAMPATH-I monoclonal antibody and E-rosetting. Br j HaematoL (1986) 62:421–430.
   PubMed Web of Science ®Google Scholar
• HAMBLIN M, MARSH JC, LAWLER M et al.: Campath-1G in vivo confers a low incidence of graft- versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors. Bone Marrow Tramp]. (1996) 17:819–824.
   PubMed Web of Science ®Google Scholar
• HALE G, WALDMANN H, FRIEND E CALNE R: Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. Transplantation (1986) 42:308–311.
   PubMed Web of Science ®Google Scholar
• CALNE R, MOFFATT SD, FRIEND PJ et al.: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 68: 1613-1616.
   Google Scholar
• KEATING MJ. BJ, RAI K, FLINN I et al:Multicentric study of campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine. Blood (1999) 94:705a.
   Web of Science ®Google Scholar
• •The largest clinical study of alemtuzumab in patients with CLL.
   Google Scholar
• OSTERBORG A, DYER MJ, BUNJES D et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. j CM]. arca (1997) 15:1567–1574.
   Google Scholar
• KENNEDY B, ROWSTROM AC, EVANS P: Campath-1H therapy in 29 patients with refractory CLL: 'true' complete remission is an attainable goal. Blood (1999) 94:603a.
   Web of Science ®Google Scholar
• OSTERBORG A, FASSAS AS, ANAGNOSTOPOULOS A, DYER MJ, CATOVSKY D, MELLSTEDT H: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br Haematal. (1996) 93:151–153.
   PubMed Web of Science ®Google Scholar
• MELLSTEDT H, OSTERBORG A, LUNDIN J etal.: Campath-1H therapy of patients with previously untreated chronic lymphocytic leukemia. Blood (1998) 92:490a.
   Google Scholar
• DYER MJ, KELSEY SM, MACKAY HJ et al.: In vivo Purging' of residual disease in CLL with Campath-1H. Br j Haematal. (1997) 97:669–672.
   PubMed Web of Science ®Google Scholar
• O'BRIEN S, THOMAS D A, CORTES J et al.: Campath-1H for minimal residual disease in CLL. Proceeding of the Annual Meeting of the American Society of Clinical Oncology (2001) 20:1132a.
   Google Scholar
• PAWSON R, DYER MJ, BARGE R et al: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. j Chi]. Orical. (1997) 15:2667–2672.
   Google Scholar
• •Clinical trial of alemtuzumab in patients with T-PLL.
   Google Scholar
• FERRAJOLI A, O'BRIEN S, KURZROCK R: Phase II clinical trial of Campath-1H in refractory hematological malignancies expressing the surface antigen CD-52. Proceeding of the Annual Meeting of the American Society of Clinical Oncology (2000) 19:22a.
   Google Scholar
• LUNDIN J, OSTERBORG A, BRITTINGER G et al: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H Treatment in low-grade Non-Hodgkin's lymphoma. I Chi]. arca (1998) 16:3257–3263.
   Google Scholar
• COLES AJ, WING MG, MOLYNEUX P et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neural (1999) 46:296–304.
   PubMed Web of Science ®Google Scholar
• COLES AJ, WING M, SMITHS et al: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 354:1691–1695.
   PubMed Web of Science ®Google Scholar
• WATTS RA, ISAACS JD, HALE G, HAZLEMAN BL, WALDMANN H: CAMPATH-1H in inflammatory arthritis. Chi]. Exp. Rheumatal. (1993) 11 (Suppl. 8):S165–S167.
   Google Scholar
• SCHNITZER TJ, YOCUM DE, MICHALSKA M etal.: Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. I Rheumatal (1997) 24:1031–1036.
   Google Scholar
• LOCKWOOD CM, THIRU S, ISAACS JD, HALE G, WALDMANN H: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet (1993) 341:1620–1622.
   PubMed Web of Science ®Google Scholar
• FLYNN JM, BYRD JC: Campath-1H monoclonal antibody therapy. Curr. Opin. Orical. (2000) 12:574–581.
   PubMed Web of Science ®Google Scholar
• MOREAU T, COLES A, WING M et al: Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 119:225–237.
   PubMed Web of Science ®Google Scholar
• FRETER C, ST. GERMAIN D, WOLFSON A: Treatment of lymphoid malignancies with Campath-1H with Campath-1H associated with elevated serum levels of IL-6 and TNF-alpha. Proceeding of the Annual Meeting of the American Socieh, of Clinical Oncology (1993) 12:1289a.
   Google Scholar
• OSTERBORG A, WERNER A, HALAPI E et al: Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur. j Haematal. (1997) 58:5–13.
   PubMed Web of Science ®Google Scholar
• DAVISON GM, NOVITZKY N, KLINE A et al.: Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation (2000) 69:1341–1347.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, MADDISON PJ, BULPITT KJ etal.: CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. (1995) 38:1589–1594.
   Google Scholar